HUE062708T2 - Dezoxi-citidin származékok rák terápiákban történõ alkalmazásra - Google Patents
Dezoxi-citidin származékok rák terápiákban történõ alkalmazásraInfo
- Publication number
- HUE062708T2 HUE062708T2 HUE20703447A HUE20703447A HUE062708T2 HU E062708 T2 HUE062708 T2 HU E062708T2 HU E20703447 A HUE20703447 A HU E20703447A HU E20703447 A HUE20703447 A HU E20703447A HU E062708 T2 HUE062708 T2 HU E062708T2
- Authority
- HU
- Hungary
- Prior art keywords
- deoxy
- cancer therapies
- cytidine derivatives
- cytidine
- derivatives
- Prior art date
Links
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical class O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1901427.3A GB2580963B (en) | 2019-02-01 | 2019-02-01 | Cancer therapies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE062708T2 true HUE062708T2 (hu) | 2023-11-28 |
Family
ID=65998012
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE20703447A HUE062708T2 (hu) | 2019-02-01 | 2020-02-03 | Dezoxi-citidin származékok rák terápiákban történõ alkalmazásra |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US11963973B2 (hu) |
| EP (2) | EP4233879A1 (hu) |
| JP (2) | JP7314289B2 (hu) |
| KR (2) | KR102653041B1 (hu) |
| CN (2) | CN118078850A (hu) |
| AU (2) | AU2020215801B2 (hu) |
| BR (1) | BR112021014898A2 (hu) |
| CA (1) | CA3126512A1 (hu) |
| DK (1) | DK3917538T3 (hu) |
| ES (1) | ES2956508T3 (hu) |
| FI (1) | FI3917538T3 (hu) |
| GB (1) | GB2580963B (hu) |
| HR (1) | HRP20230823T1 (hu) |
| HU (1) | HUE062708T2 (hu) |
| IL (1) | IL285207A (hu) |
| LT (1) | LT3917538T (hu) |
| MX (1) | MX2021009206A (hu) |
| PL (1) | PL3917538T3 (hu) |
| PT (1) | PT3917538T (hu) |
| RS (1) | RS64515B1 (hu) |
| SG (1) | SG11202107281XA (hu) |
| SI (1) | SI3917538T1 (hu) |
| WO (1) | WO2020157335A1 (hu) |
| ZA (1) | ZA202106190B (hu) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020334060A1 (en) * | 2019-08-19 | 2022-03-24 | Zogenix, Inc. | Polymorphic forms of deoxycytidine, compositions comprising the same and uses |
| WO2023068404A1 (ko) * | 2021-10-21 | 2023-04-27 | 한국생명공학연구원 | Eml4-alk 양성 비소세포폐암 환자의 치료 약물 선택을 위한 정보 제공 방법 및 alk 저해제 내성 비소세포폐암 치료용 조성물 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE114949C (hu) | ||||
| DD114949A1 (hu) * | 1974-09-23 | 1975-09-05 | ||
| US4148889A (en) * | 1976-12-08 | 1979-04-10 | Canadian Patents And Development Limited | Treatment of viral infections |
| US5545629A (en) * | 1994-04-12 | 1996-08-13 | Montefiore Medical Center | 5-ethoxy-2'-deoxyuridines |
| WO1996026743A1 (en) * | 1995-03-01 | 1996-09-06 | Human Gene Therapy Research Institute | Radiation enhanced gene therapy for treatment of tumors |
| CN1205640A (zh) * | 1995-12-22 | 1999-01-20 | 东卡罗来纳大学 | 治疗以胞苷脱氨酶或脱氧胞苷脱氨酶过量表达为特征的失调的方法 |
| US6136791A (en) | 1995-12-22 | 2000-10-24 | East Carolina University | Agent and method for treating disorders associated with cytidine deaminase or deoxycytidine deaminase overexpression |
| EP1156827B1 (en) | 1999-03-01 | 2006-09-20 | Halogenetics, Inc. | USE OF COMPOSITIONS COMPRISING CldC AS RADIOSENSITIZERS IN THE TREATMENT OF NEOPLASTIC DISEASES |
| AU6792700A (en) * | 1999-08-20 | 2001-03-19 | Research Foundation Of The State University Of New York, The | 5-propynylpyrimidine derivatives as cytotoxic enzyme inhibitors |
| WO2008085611A2 (en) * | 2006-11-27 | 2008-07-17 | University Of Miami | Designer theraphy of pancreatic tumors |
| LT5708B (en) * | 2009-04-02 | 2011-01-25 | Biotechnologijos Inst | Derivatization of biomolecules by covalent coupling of non-cofactor compounds using methyltransferases |
| US8617540B2 (en) * | 2009-04-15 | 2013-12-31 | Fox Chase Cancer Center | Combinational chemotherapy treatment |
| CN102191233B (zh) * | 2010-03-04 | 2014-06-04 | 中国人民解放军军事医学科学院毒物药物研究所 | 新颖的10-23脱氧核酶类似物及其用途 |
| US20110230433A1 (en) * | 2010-03-16 | 2011-09-22 | University Of Washington | Compositions and methods for treatment of cancer |
| HUE026235T2 (hu) | 2010-03-31 | 2016-06-28 | Gilead Pharmasset Llc | Krisztallin (S)-izopropil 2-(((S)-(((2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihidropirimidin-1-(2H)-IL)-4-fluor-3-hidroxi- 4-metiltetrahidrofuran-2-IL)metoxi)(fenoxi)foszforil)amino)propanoat |
| JP2013230985A (ja) * | 2010-08-20 | 2013-11-14 | Osaka Univ | ５−ホルミル核酸の生成方法 |
| EP2638048A1 (en) * | 2010-11-12 | 2013-09-18 | Ludwig-Maximilians-Universität München | Nucleic acidsbuilding blocks and methods for the synthesis of 5-hydroxymethylcytosine-containing |
| CN102125579B (zh) * | 2010-12-22 | 2013-12-11 | 中国科学院广州生物医药与健康研究院 | 5位修饰的2’脱氧胞苷衍生物或其磷酸盐在制药中的新应用 |
| EP3682905B1 (en) | 2011-10-03 | 2021-12-01 | ModernaTX, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| US8949307B2 (en) | 2011-11-15 | 2015-02-03 | Google Inc. | Cloud-to-device messaging for application activation and reporting |
| WO2014194250A2 (en) * | 2013-05-31 | 2014-12-04 | University Of Cincinnati | Novel nanocarrier delivered cancer chemotherapeutic agents |
| US10086010B2 (en) * | 2014-03-18 | 2018-10-02 | Stc.Unm | Synergistic enhancement of 5-fluorouracil cytotoxicity by deoxyuridine analogs in cancer cells |
| CN104592333B (zh) * | 2014-07-23 | 2017-06-27 | 江西科技师范大学 | 一种合成5‑羧基‑2’‑脱氧胞苷的方法 |
| CZ309218B6 (cs) * | 2014-08-26 | 2022-06-01 | Univerzita Palackého v Olomouci | Způsob stanovení aktivity enzymů přeměňujících cytosinové deriváty na uracilové deriváty v buňkách a tkáních |
| DE102014113936A1 (de) * | 2014-09-25 | 2016-03-31 | Christoph Pallua | Krebsmedikament |
| US20190328783A1 (en) * | 2016-04-15 | 2019-10-31 | Cellectis | A method of engineering prodrug-specific hypersensitive t-cells for immunotherapy by gene expression |
| AU2017354876A1 (en) * | 2016-11-04 | 2019-06-20 | Qiagen Sciences, Llc | Thiol-containing cleave reagents and oxidative wash |
| GB201913030D0 (en) | 2019-09-10 | 2019-10-23 | Francis Crick Institute Ltd | Treatment of hr deficient cancer |
-
2019
- 2019-02-01 GB GB1901427.3A patent/GB2580963B/en active Active
-
2020
- 2020-02-03 US US17/427,542 patent/US11963973B2/en active Active
- 2020-02-03 EP EP23174101.8A patent/EP4233879A1/en active Pending
- 2020-02-03 BR BR112021014898-1A patent/BR112021014898A2/pt unknown
- 2020-02-03 WO PCT/EP2020/052632 patent/WO2020157335A1/en unknown
- 2020-02-03 FI FIEP20703447.1T patent/FI3917538T3/fi active
- 2020-02-03 MX MX2021009206A patent/MX2021009206A/es unknown
- 2020-02-03 CN CN202410273651.1A patent/CN118078850A/zh active Pending
- 2020-02-03 KR KR1020217027066A patent/KR102653041B1/ko active IP Right Grant
- 2020-02-03 RS RS20230588A patent/RS64515B1/sr unknown
- 2020-02-03 PL PL20703447.1T patent/PL3917538T3/pl unknown
- 2020-02-03 KR KR1020247010119A patent/KR20240046612A/ko active Search and Examination
- 2020-02-03 DK DK20703447.1T patent/DK3917538T3/da active
- 2020-02-03 ES ES20703447T patent/ES2956508T3/es active Active
- 2020-02-03 EP EP20703447.1A patent/EP3917538B1/en active Active
- 2020-02-03 SI SI202030240T patent/SI3917538T1/sl unknown
- 2020-02-03 CA CA3126512A patent/CA3126512A1/en active Pending
- 2020-02-03 JP JP2021544852A patent/JP7314289B2/ja active Active
- 2020-02-03 HU HUE20703447A patent/HUE062708T2/hu unknown
- 2020-02-03 LT LTEPPCT/EP2020/052632T patent/LT3917538T/lt unknown
- 2020-02-03 HR HRP20230823TT patent/HRP20230823T1/hr unknown
- 2020-02-03 CN CN202080011688.7A patent/CN113543789B/zh active Active
- 2020-02-03 SG SG11202107281XA patent/SG11202107281XA/en unknown
- 2020-02-03 AU AU2020215801A patent/AU2020215801B2/en active Active
- 2020-02-03 PT PT207034471T patent/PT3917538T/pt unknown
-
2021
- 2021-07-28 IL IL285207A patent/IL285207A/en unknown
- 2021-08-26 ZA ZA2021/06190A patent/ZA202106190B/en unknown
-
2023
- 2023-07-11 JP JP2023113931A patent/JP2023153793A/ja active Pending
- 2023-08-02 AU AU2023210586A patent/AU2023210586A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282663A (en) | BT1718 for use in cancer treatment | |
| IL251630A0 (en) | Combined therapy for use in cancer treatment | |
| EP3713585A4 (en) | MSC-EXPRESSED IMMUNE MODULATORS IN COMBINATION WITH CAR-T FOR CANCER THERAPY | |
| IL288728A (en) | Anti-sortilin antibodies for use in therapy | |
| EP3371201A4 (en) | Conjugated antisense compounds for use in therapy | |
| SG11202011261PA (en) | Urolithin a and derivatives thereof for use in therapy | |
| PL3253208T3 (pl) | Terapie kombinowane do zastosowania w leczeniu nowotworu piersi | |
| IL267159B (en) | A pharmaceutical preparation containing e7386 given in combination with lanuatinib for the treatment of tumors | |
| EP3430057A4 (en) | USE OF APE1 / REF-1 INHIBITORS IN COMBINATION THERAPIES FOR TREATING CANCER | |
| IL282093A (en) | Combination therapy for cancer | |
| IL282294A (en) | Combinations for immune modulation in cancer treatment | |
| IL280830A (en) | Bracelets for use in cancer treatment methods | |
| GB201905780D0 (en) | Cancer therapy | |
| ZA202106190B (en) | Deoxy- cytidine or uridine derivatives for use in cancer therapies | |
| EP3708173C0 (en) | PHARMACEUTICAL COMPOSITION COMPRISING MIRNA-3140 FOR THE TREATMENT OF CANCER | |
| SG11202106295WA (en) | Compositions and methods for cancer therapy | |
| IL284981A (en) | Antagonists to semaphorin-4d for use in cancer therapy | |
| ZA202007955B (en) | Ccr5 inhibitor for use in treating cancer | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| GB201821147D0 (en) | Mirna for use in therapy | |
| IL285538A (en) | Combined therapies for use in cancer treatment | |
| IL283687A (en) | usp19 inhibitors and their use for therapeutic purposes | |
| IL306090A (en) | Targeted cancer treatments | |
| GB201615844D0 (en) | Agents for use in therapy | |
| IL278921A (en) | Combined treatments for cancer |